Exploring Noninvasive Assessment of Plaque Burden and Emerging Lipid-Lowering Agents in Cardiology

In this chapter, discussions center around noninvasive methods for identifying obstructive coronary disease, interpreting calcium scores, and employing coronary CT for risk reclassification. The conversation also delves into the role of emerging lipid-lowering agents in quantifying plaque burden, emphasizing the importance of LDL reduction in heart health and exploring the potential impact of novel medications like PCSK9 inhibitors, siRNA inhibitors, and ATP citrate lysin inhibitors on plaque morphology.